van Santbrink Evert J P, Fauser Bart C J M
Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):261-70. doi: 10.1016/j.beem.2006.03.002.
Treatment of normogonadotropic anovulatory infertility (World Health Organization class 2, or WHO2) is by induction of ovulation using clomiphene citrate (CC), followed by follicle-stimulating hormone (FSH) in cases of treatment failure. Not all patients will become ovulatory or will conceive with this treatment. Others, exhibiting multifollicular instead of monofollicular development, may encounter complications such as ovarian hyperstimulation and multiple pregnancy. Recently introduced alternative treatment interventions-such as insulin-sensitizing drugs, aromatase inhibitors, or laparoscopic electrocautery of the ovaries-may offer the possibility of improving the efficacy of the classical ovulation induction algorithm. Based on initial patient characteristics, it may be possible to identify specific patient subgroups with altered chances of success or complications while using one of these interventions. Regarding CC and FSH ovulation induction, this has been performed using multivariate prediction models. This approach may enable us to improve safety, cost-effectiveness, and patient convenience in future ovulation induction.
对正常促性腺激素性无排卵不孕症(世界卫生组织2类,即WHO2)的治疗是使用枸橼酸氯米芬(CC)诱导排卵,治疗失败时则使用促卵泡激素(FSH)。并非所有患者经此治疗都会排卵或受孕。其他患者表现为多卵泡而非单卵泡发育,可能会出现诸如卵巢过度刺激和多胎妊娠等并发症。最近引入的替代治疗干预措施,如胰岛素增敏药物、芳香化酶抑制剂或卵巢腹腔镜电灼术,可能为提高经典排卵诱导方案的疗效提供可能。根据患者的初始特征,在使用这些干预措施之一时,有可能识别出成功几率或并发症发生几率有所改变的特定患者亚组。关于CC和FSH诱导排卵,这已通过多变量预测模型来进行。这种方法可能使我们在未来的排卵诱导中提高安全性、成本效益和患者便利性。